Medicines Company v. Hospira, Inc., No. 14-1469 (Fed. Cir. July 2, 2015)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

The Medicines Company appeals the U.S. District Court for the District of Delaware’s claim construction and non-infringement finding s. Hospira , Inc. cross- appeals the district court’s determination that the asser t- ed claims are not invalid under the on -sale bar, obviou s- ness, or indefiniteness . We conclude that the district court clearly erred in finding that the bivalirudin batches prepared by Ben Venue Laboratories before the critical date were not sold to The Medicines Company and were prepared primarily for an experimental purpose.